Department of Thoracic Surgery, St James's University Hospital Bexley Wing, Leeds, United Kingdom.
Department of Thoracic Surgery, St James's University Hospital Bexley Wing, Leeds, United Kingdom.
J Thorac Cardiovasc Surg. 2021 Mar;161(3):776-786. doi: 10.1016/j.jtcvs.2020.06.151. Epub 2020 Aug 24.
The study objective was to verify whether the Eurolung score was associated with long-term prognosis after lung cancer resection.
A total of 1359 consecutive patients undergoing anatomic lung resection (1136 lobectomies, 103 pneumonectomies, 120 segmentectomies) (2014-2018) were analyzed. The parsimonious aggregate Eurolung2 score was calculated for each patient. Median follow-up was 802 days. Survival distribution was estimated by the Kaplan-Meier method. Cox proportional hazard regression and competing risk regression analyses were used to assess the independent association of Eurolung with overall and disease-specific survival.
Patients were grouped into 4 classes according to their Eurolung scores (A 0-2.5, B 3-5, C 5.5-6.5, D 7-11.5). Most patients were in class A (52%) and B (33%), 8% were in class C, and 7% were in class D. Five-year overall survival decreased across the categories (A: 75%; B: 52%; C: 29%; D: 27%, log rank P < .0001). The score stratified the 3-year overall survival in patients with pT1 (P < .0001) or pT>1 (P < .0001). In addition, the different classes were associated with incremental risk of long-term overall mortality in patients with pN0 (P < .0001) and positive nodes (P = .0005). Cox proportional hazard regression and competing regression analyses showed that Eurolung aggregate score remained significantly associated with overall (hazard ratio, 1.19; P < .0001) and disease-specific survival after adjusting for pT and pN stage (hazard ratio, 1.09; P = .005).
Eurolung aggregate score was associated with long-term survival after curative resection for cancer. This information may be valuable to inform the shared decision-making process and the multidisciplinary team discussion assisting in the selection of the most appropriate curative treatment in high-risk patients.
本研究旨在验证 Eurolung 评分是否与肺癌切除术后的长期预后相关。
共分析了 1359 例连续接受解剖性肺切除术(1136 例肺叶切除术、103 例全肺切除术、120 例肺段切除术)(2014-2018 年)的患者。为每位患者计算了简明综合 Eurolung2 评分。中位随访时间为 802 天。生存分布采用 Kaplan-Meier 法估计。Cox 比例风险回归和竞争风险回归分析用于评估 Eurolung 与总生存率和疾病特异性生存率的独立相关性。
根据 Eurolung 评分,患者分为 4 组(A 0-2.5、B 3-5、C 5.5-6.5、D 7-11.5)。大多数患者处于 A 组(52%)和 B 组(33%),8%处于 C 组,7%处于 D 组。随着类别增加,5 年总生存率降低(A:75%;B:52%;C:29%;D:27%,log rank P<.0001)。该评分在 pT1(P<.0001)或 pT>1(P<.0001)患者中分层了 3 年总生存率。此外,不同类别与 pN0(P<.0001)和阳性淋巴结(P=.0005)患者的长期总死亡率增加相关。Cox 比例风险回归和竞争回归分析显示,调整 pT 和 pN 分期后,Eurolung 综合评分与总生存率(风险比,1.19;P<.0001)和疾病特异性生存率(风险比,1.09;P=.005)仍显著相关。
Eurolung 综合评分与癌症根治性切除术后的长期生存相关。这些信息对于辅助高危患者的治疗选择可能具有重要意义,有助于知情决策和多学科团队讨论。